Serum myostatin is reduced in individuals with metabolic syndrome.

Myostatin is a negative regulator of skeletal muscle mass and may also modulate energy metabolism secondarily. We aim to investigate the relationship between serum myostatin and the metabolic variables in diabetic (DM) and non-diabetic subjects.A cross-sectional study recruiting 246 consecutive DM p...

Full description

Bibliographic Details
Main Authors: Der-Sheng Han, Yu Chu-Su, Chih-Kang Chiang, Fen-Yu Tseng, Ping-Huei Tseng, Chi-Ling Chen, Kwan-Dun Wu, Wei-Shiung Yang
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2014-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4177900?pdf=render
id doaj-9b18b6073b854ba29ef46038a3ff179a
record_format Article
spelling doaj-9b18b6073b854ba29ef46038a3ff179a2020-11-24T21:50:36ZengPublic Library of Science (PLoS)PLoS ONE1932-62032014-01-0199e10823010.1371/journal.pone.0108230Serum myostatin is reduced in individuals with metabolic syndrome.Der-Sheng HanYu Chu-SuChih-Kang ChiangFen-Yu TsengPing-Huei TsengChi-Ling ChenKwan-Dun WuWei-Shiung YangMyostatin is a negative regulator of skeletal muscle mass and may also modulate energy metabolism secondarily. We aim to investigate the relationship between serum myostatin and the metabolic variables in diabetic (DM) and non-diabetic subjects.A cross-sectional study recruiting 246 consecutive DM patients and 82 age- and gender-matched non-diabetic individuals at a medical center was conducted. The variables of anthropometry and blood chemistry were obtained. Serum myostatin level was measured with enzyme immunoassay.DM group had lower serum myostatin compared with non-diabetics (7.82 versus 9.28 ng/ml, p<0.01). Sixty-two percent of the recruited individuals had metabolic syndrome (MetS). The patients with MetS had significantly lower serum myostatin than those without (7.39 versus 9.49 ng/ml, p<0.001). The serum myostatin level decreased with increasing numbers of the MetS components (p for trend<0.001). The patients with higher body mass index, larger abdominal girth, lower high-density lipoprotein cholesterol (HDL-C), and higher triglycerides had lower serum myostatin than those without. The serum myostatin level was independently negatively related to larger abdominal girth, higher triglycerides, and lower HDL-C after adjustment. The odds ratios for MetS, central obesity, low HDL-C, high triglycerides, and DM were 0.85, 0.88, 0.89, 0.85, and 0.92, respectively, when serum myostatin increased per 1 ng/mL, in the binary logistic regression models.Lower serum myostatin independently associated with MetS, central obesity, low HDL-C, and high triglycerides after adjustment. Higher serum myostatin is associated with favorable metabolic profiles.http://europepmc.org/articles/PMC4177900?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Der-Sheng Han
Yu Chu-Su
Chih-Kang Chiang
Fen-Yu Tseng
Ping-Huei Tseng
Chi-Ling Chen
Kwan-Dun Wu
Wei-Shiung Yang
spellingShingle Der-Sheng Han
Yu Chu-Su
Chih-Kang Chiang
Fen-Yu Tseng
Ping-Huei Tseng
Chi-Ling Chen
Kwan-Dun Wu
Wei-Shiung Yang
Serum myostatin is reduced in individuals with metabolic syndrome.
PLoS ONE
author_facet Der-Sheng Han
Yu Chu-Su
Chih-Kang Chiang
Fen-Yu Tseng
Ping-Huei Tseng
Chi-Ling Chen
Kwan-Dun Wu
Wei-Shiung Yang
author_sort Der-Sheng Han
title Serum myostatin is reduced in individuals with metabolic syndrome.
title_short Serum myostatin is reduced in individuals with metabolic syndrome.
title_full Serum myostatin is reduced in individuals with metabolic syndrome.
title_fullStr Serum myostatin is reduced in individuals with metabolic syndrome.
title_full_unstemmed Serum myostatin is reduced in individuals with metabolic syndrome.
title_sort serum myostatin is reduced in individuals with metabolic syndrome.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2014-01-01
description Myostatin is a negative regulator of skeletal muscle mass and may also modulate energy metabolism secondarily. We aim to investigate the relationship between serum myostatin and the metabolic variables in diabetic (DM) and non-diabetic subjects.A cross-sectional study recruiting 246 consecutive DM patients and 82 age- and gender-matched non-diabetic individuals at a medical center was conducted. The variables of anthropometry and blood chemistry were obtained. Serum myostatin level was measured with enzyme immunoassay.DM group had lower serum myostatin compared with non-diabetics (7.82 versus 9.28 ng/ml, p<0.01). Sixty-two percent of the recruited individuals had metabolic syndrome (MetS). The patients with MetS had significantly lower serum myostatin than those without (7.39 versus 9.49 ng/ml, p<0.001). The serum myostatin level decreased with increasing numbers of the MetS components (p for trend<0.001). The patients with higher body mass index, larger abdominal girth, lower high-density lipoprotein cholesterol (HDL-C), and higher triglycerides had lower serum myostatin than those without. The serum myostatin level was independently negatively related to larger abdominal girth, higher triglycerides, and lower HDL-C after adjustment. The odds ratios for MetS, central obesity, low HDL-C, high triglycerides, and DM were 0.85, 0.88, 0.89, 0.85, and 0.92, respectively, when serum myostatin increased per 1 ng/mL, in the binary logistic regression models.Lower serum myostatin independently associated with MetS, central obesity, low HDL-C, and high triglycerides after adjustment. Higher serum myostatin is associated with favorable metabolic profiles.
url http://europepmc.org/articles/PMC4177900?pdf=render
work_keys_str_mv AT dershenghan serummyostatinisreducedinindividualswithmetabolicsyndrome
AT yuchusu serummyostatinisreducedinindividualswithmetabolicsyndrome
AT chihkangchiang serummyostatinisreducedinindividualswithmetabolicsyndrome
AT fenyutseng serummyostatinisreducedinindividualswithmetabolicsyndrome
AT pinghueitseng serummyostatinisreducedinindividualswithmetabolicsyndrome
AT chilingchen serummyostatinisreducedinindividualswithmetabolicsyndrome
AT kwandunwu serummyostatinisreducedinindividualswithmetabolicsyndrome
AT weishiungyang serummyostatinisreducedinindividualswithmetabolicsyndrome
_version_ 1725882799293988864